The California legislature has passed SB 17, a major effort to ensure transparency in drug pricing. Brown is expected to make a decision on whether to sign both bills by mid-October. In the last few years, pharmaceutical companies have been increasingly aggressive about marketing their drugs and devices for use by people with chronic conditions, including cancer, diabetes, heart disease, Alzheimer’s disease and other conditions.
The California legislature has passed SB 17, a major effort to ensure transparency in drug pricing. In the last few years, pharmaceutical companies have been increasingly aggressive about marketing their drugs and devices for use by people with chronic conditions, including cancer, diabetes, heart disease, Alzheimer’s disease and other conditions.